Drug Discovery World

NOVEMBER 6, 2023

Both parties will have the opportunity to identify and nominate potential projects for clinical development. In particular, the alliance will focus on projects featuring a novel, promising, academic-derived agent which has the potential to address a high unmet clinical need.

Research 130

Research Clinical Trials Clinical Development International 130

Drug Discovery World

JANUARY 10, 2024

The acquisition includes Aiolos’ AIO-001, a potentially best-in-class, long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody ready to enter Phase II clinical development for asthma, with potential for additional indications.

Pharmacokinetics 130

Pharmacokinetics Licensing Licensing Clinical Development 130

The Pharma Data

JANUARY 5, 2021

COVID-19 have caused delays to submission and processing of the regulatory application to initiate clinical development in China. Due to the unforeseen delays, Targovax has extended the term of IOvaxis’s license option by 3 months, otherwise the agreement remains unchanged.

Licensing 40

Licensing Licensing Vaccine Clinical Development 40

Drug Discovery World

JUNE 1, 2023

BB-1701 is an ADC that is composed of Eisai’s in-house developed anticancer agent eribulin, and anti-HER2 antibody using a linker, and is expected to have anti-tumour effects on breast, lung and other solid tumors that express HER2.

Marketing 245

Marketing FDA Approval Licensing Licensing 245

Drug Discovery World

MAY 3, 2023

This financing will enable us to ensure a broad development program of our lead asset uPARAP and further advance our 2nd first-in-class ADC pipeline asset.” The expression profile and internalising properties of uPARAP make it an attractive ADC target.

Licensing 130

Licensing Licensing Clinical Development Therapies 130

Drug Discovery World

JANUARY 15, 2024

For an additional $28 million, Lantheus has obtained an option to exclusively license Perspective’s neuroendocrine tumours treatment Pb212-VMT-⍺-NET, or to co-develop certain early stage therapeutic candidates targeting prostate cancer. of Perspective’s shares for up to $33 million.

Targeted Protein Degradation 148

Targeted Protein Degradation Small Molecule Drugs Licensing 148

Drug Discovery World

AUGUST 14, 2023

Research partners in the UK are progressing their orally available small molecule cancer immunotherapy drug into clinical development as a treatment for advanced solid tumours. HTL0039732 works by blocking signalling through a specific type of prostaglandin receptor, the prostaglandin E2 (PGE2)-type prostanoid receptor 4 (EP4).

Trials 130

Trials Small Molecule Pharmacokinetics Clinical Trials 130

Drug Discovery World

FEBRUARY 27, 2023

Under a new agreement, Destiny Pharma and Sebela Pharmaceuticals will co-develop NTCD-M3, Destiny’s lead asset for the prevention of Clostridioides difficile infection (CDI) recurrence. Patients who have taken NTCD-M3 were found to be protected from toxic strains of CDI.

Clinical Trials 130

Clinical Trials Licensing Licensing Drugs 130

Drug Discovery World

JULY 26, 2023

” With the safety of MOv18 IgE having been established in cancer patients, biotechnology company Epsilogen has licensed the drug and will continue its clinical development.

Clinical Trials 130

Clinical Trials Immune Response Trials Drugs 130

The Pharma Data

JUNE 2, 2022

Boehringer Ingelheim and the Agency for Science, Technology and Research (A*STAR) today announced a global licensing agreement under which Boehringer Ingelheim will obtain exclusive worldwide rights to research, develop and commercialize products based on a panel of innovative, tumor-specific antibodies from A*STAR.

Licensing 52

Licensing Licensing Therapies Science 52

The Pharma Data

NOVEMBER 4, 2020

Ltd (“Juyou”), a biotechnology company that develops and sells medical and cosmetic skincare products, for the commercialization and development of Pliaglis ® in mainland China (the “License Agreement”). million and US$1.8

Licensing 40

Licensing Licensing Production Engineering 40

Drug Target Review

SEPTEMBER 5, 2024

This role gave me a good understanding of how important IP/patent and global marketing are for the brand but also the importance of emerging markets and co-development and out-licensing to other pharma companies. Already, three candidates are in clinical development and the lead candidate is ready to enter Phase III.

Pharma Companies 105

Pharma Companies Licensing Licensing Disease 105

Drug Discovery World

DECEMBER 20, 2022

The clinical development of etranacogene dezaparvovec was led by uniQure and sponsorship of the clinical trials transitioned to CSL after it licensed global rights to commercialise the treatment. . Following infusion of etranacogene dezaparvovec, 96% of patients discontinued routine FIX prophylaxis. .

Therapies 130

Therapies Clinical Trials Licensing Licensing 130

Drug Discovery World

JUNE 5, 2023

Ariceum Therapeutics, a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, has acquired Theragnostics, a UK-based private biopharmaceutical company engaged in the development of radio-labelled PARP inhibitors for the diagnosis and treatment of tumours.

FDA Approval 130

FDA Approval FDA DNA Licensing 130

The Pharma Data

MAY 7, 2021

The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the U.S. Food and Drug Administration (FDA), but has been authorized for emergency use by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 16 years of age and older.

Licensing 52

Licensing Licensing Vaccine FDA Approval 52

Drug Discovery World

NOVEMBER 8, 2022

Merck has exercised its option to jointly develop and commercialise personalised cancer vaccine (PCV) mRNA-4157/V940 pursuant to the terms of its existing collaboration and license agreement with Moderna. .

Vaccine 130

Vaccine Immune Response Research Laboratories Clinical Trials 130

Drug Discovery World

MARCH 24, 2023

Regulatory approval The company and the US Food and Drug Administration (FDA) agreed to the integrated Phase II/III trial design for AIPAC-003 that will help inform a Biologics License Application (BLA). The Phase III will have overall survival as the primary objective and may include a specific patient population.

Trials 130

Trials Immune Response FDA Clinical Development 130

Drug Discovery World

MAY 29, 2024

For biotechs, partnerships with pharmas provide a source of income, useful technical knowledge, and a path to progress programs into the later stages of clinical development and commercialisation, the latter of which the biotech is unlikely to be able to do on its own. The entire team from Good moved to Bonum.

International 148

International Licensing Licensing Regulations 148

Drug Discovery World

AUGUST 12, 2022

VLA15 is the only Lyme disease vaccine candidate currently in clinical development. If the Phase III trial is successful, Pfizer aims to submit a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) and Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) in 2025. .

Vaccine 130

Vaccine Disease Trials Pharmaceutical Companies 130

The Pharma Data

NOVEMBER 30, 2020

1, 2020 /PRNewswire/ — Sosei Group Corporation (“the Company”) (TSE: 4565) announces it has entered into a global collaboration and license agreement with Biohaven Pharmaceutical Holding Company Ltd. (“Biohaven”, NYSE: BHVN). . TOKYO and CAMBRIDGE, England , Dec. GPCR – G protein-coupled receptors.

Small Molecule 40

Small Molecule Licensing Licensing Clinical Trials 40

Drug Discovery World

MARCH 13, 2024

Data from the Phase IIb FRONTIER 1 study evaluating JNJ-2113 in adults with moderate-to-severe PsO were recently published in The New England Journal of Medicine.

Trials 130

Trials Clinical Trials Treatment Licensing 130

Drug Discovery World

MARCH 7, 2023

She has over 15 years’ experience in corporate finance and restructurings, mergers and acquisitions, joint ventures and intellectual property licensing. Linda Powers, CEO, Northwest Biotherapeutics Powers has served as the Chairman of NW Bio since 2007, and as CEO since 2011.

International 246

International Science Pharmaceuticals DNA 246

Drug Discovery World

SEPTEMBER 14, 2023

joined Pfizer’s Executive Leadership Team as Chief Oncology Research and Development Officer and Executive Vice President reporting to Chairman and Chief Executive Officer, Albert Bourla.

Vaccine 148

Vaccine FDA Approval Drugs Licensing 148

Drug Discovery World

JULY 2, 2024

In another example, university of Basel spin-off T3 Pharma reached Phase I development of a cancer therapy that harnesses the natural behaviours of live bacteria before being acquired by Boehringer Ingelheim for $509m at the end of 2023. Biopôle Lausanne has been created to provide a focus for life sciences activity in the region.

Science 148

Science Drugs Clinical Trials Licensing 148

Drug Discovery World

OCTOBER 4, 2022

“While AD remains a huge area of opportunity for drug developers, we believe that the rare neurodegenerative disease space, specifically rare tauopathies, is a sector that is in critical need for better diagnosis and effective therapeutics. Diseases such as PSP and FTD have no licensed and available treatments. William Erhardt, M.D.,

Disease 130

Disease Small Molecule Compound Screening Clinical Development 130

Drug Target Review

APRIL 9, 2024

Among other discoveries, the group developed inhibitors of the ATR kinase and showed their potential for cancer therapy. These compounds were later licensed to the pharmaceutical industry for clinical development.

RNA 64

RNA Cell Biology Clinical Development DNA 64

Drug Discovery World

FEBRUARY 28, 2024

With the safety of MOv18 IgE having been established in cancer patients, biotechnology company Epsilogen has licensed the drug and will continue its clinical development following this successful clinical trial.

Drug Development 163

Drug Development Research Clinical Trials Drugs 163

Drug Discovery World

JULY 22, 2024

In addition to BSB-1001, BlueSphere has also discovered and nominated three additional miHA-targeting TCRs for clinical development, all for use in the same clinical setting as BSB-1001. His experience includes raising capital in public markets and closing various deals, such as licenses and strategic collaborations.

Therapies 130

Therapies Engineering Treatment Pharma Companies 130

Drug Discovery World

JANUARY 5, 2023

“The novel hSMN1 AAV gene therapy vector, consisting of the endogenous SMN1 promoter and codon-optimised hSMN1, has a remarkably improved potency and safety profile as compared to the benchmark vector, holding great promise for further clinical development,” said Guangping Gao, the Penelope Booth Rockwell Professor in Biomedical Research, Professor (..)

Therapies 130

Therapies Medical Schools Clinical Development Pharmaceuticals 130

Drug Discovery World

NOVEMBER 9, 2023

For patients with ‘cold’ tumours where there is a paucity of killer T-cells, or in ‘hot’ tumours that have become resistant to licensed checkpoint inhibitors, there are currently very few effective therapeutic options available.

Engineering 163

Engineering Clinical Trials Licensing Licensing 163

The Pharma Data

JANUARY 12, 2021

Boehringer Ingelheim has announced it has signed a collaboration and licensing deal with Enara Bio to advance novel targeted cancer immunotherapies. According to Enara, Dark Antigens can potentially be developed as targets for immunotherapy agents. Michael Vi/Shutterstock.

Research 52

Research Licensing Licensing Vaccine 52

The Pharma Data

AUGUST 10, 2020

Novavax is partnering up with the Serum Institute of India Private Limited (SIIPL) in a licensing deal to development and marketing of up to one billion doses of its potential recombinant COVID-19 vaccine candidate, NVX?CoV2373.

Vaccine 52

Vaccine Licensing Licensing Clinical Development 52

The Pharma Data

JANUARY 25, 2021

26, 2021 /PRNewswire/ — Asieris Pharmaceuticals announced today that the company has entered into a license agreement with Photocure ASA (Photocure, PHO: OSE) to exclusively register and commercialize Hexvix® in Mainland China and Taiwan. SHANGHAI , Jan. ” About Photocure ASA.

Licensing 40

Licensing Licensing Clinical Development Pharmaceutical Companies 40

The Pharma Data

JUNE 7, 2023

Acuitas’ proprietary LNP technology is used in multiple vaccines and therapeutics in clinical development and was also used in some of the COVID-19 vaccines that were approved and administered to people in 180 countries. LNPs are spheric drug delivery bodies which can be equipped with therapeutic payloads for intracellular delivery.

Therapies 40

Therapies RNA Licensing Licensing 40

Conversations in Drug Development Trends

FEBRUARY 21, 2024

During clinical development, new chemical entities (NCEs) require an absorption, metabolism, and excretion (AME) study.

Clinical Trials 80

Clinical Trials Pharmacy Clinical Pharmacology FDA 80

LifeSciVC

JULY 17, 2024

Fortunately, AbbVie felt the same way, which is why we initiated discussions to in-license AbbVie’s most promising CF pipeline programs. We obtained exclusive worldwide rights to develop and commercialize multiple clinical-stage compounds, including two that have completed Phase 2 studies.

Clinical Research 45

Clinical Research Disease Research Clinical Trials 45

The Pharma Data

DECEMBER 21, 2020

Legend will receive $75 million from J&J as a clinical development-based milestone payment, per a 2017 collaboration pact.

Therapies 40

Therapies Licensing Licensing FDA 40